No actionable change from this filing. Guidance is unchanged, earnings risk remains on execution of existing forecasts. Monitor Pfizer's Q2 2026 earnings for any revision to FY2026 guidance or updates on the CFO search.
PFE drugs
PFE drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 18 $25.21entry
- T+1 · 5mo ago −0.52%α −0.20% · $25.08
- T+5 · 5mo ago −6.11%α −4.44% · $23.67
- T+20 · 4mo ago −0.28%α −0.81% · $25.14
- T+60 · 2mo ago +9.96%α +8.06% · $27.72
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Pfizer reaffirms full-year 2026 guidance following the CFO transition announcement on June 18, 2026. Revenue guidance remains $59.5-$62.5B and adjusted diluted EPS at $2.80-$3.00, unchanged from prior communication. This is a routine confirmation filing with no new material financial data.
Key Facts
- FY2026 revenue guidance reaffirmed at $59.5-$62.5B
- FY2026 adjusted diluted EPS guidance reaffirmed at $2.80-$3.00
- CFO transition announced on June 18, 2026, prompted this reaffirmation
Financial Impact
No new financial data; previously guided revenue and EPS ranges unchanged.
Risk Factors
- Future earnings miss could pressure stock if revenue or EPS fall below guided ranges
- CFO transition adds management uncertainty, potentially affecting execution
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000078003-26-000087 |
| Document: 0000078003-26-000087-index-headers.html | 0000078003-26-000087 |
| Document: 0000078003-26-000087-index.html | 0000078003-26-000087 |
| Document: 0000078003-26-000087.txt | 0000078003-26-000087 |
Track record
21 reports on PFE
5 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +17.28% at T+60 after the Aug 4, 2026 report. 7 of 9 went positive at some point.
Filters
- Nov 3, 202613d ago 8-K Neutral 2/10 Entry $30.79 Now $28.89 −6.17% settles Feb 2
- Nov 3, 202613d ago 8-K Bullish 6/10 Entry $30.00 Now $28.89 −3.70% settles Feb 1
- Oct 30, 202618d ago Court Ruling Neutral 2/10 Entry $30.67 Now $28.89 −5.80% settles Jan 29
- Oct 23, 202624d ago Institutional Cluster Mixed 3/10 Entry $30.03 Now $28.89 −3.80% settles Jan 21
- Aug 13, 202613w ago Court Ruling Neutral 1/10 Entry $26.79 to $29.23 Now $28.89 +7.84% ▲ +9.11% +12.15% vs SPY
- Aug 12, 202613w ago Insider Buy Bullish 5/10 Entry $26.80 to $29.39 Now $28.89 +7.80% ▲ +9.66% +15.14% vs SPY
- Aug 12, 202613w ago Insider Cluster Bullish 6/10 Entry $26.80 to $29.39 Now $28.89 +7.80% ▲ +9.66% +15.14% vs SPY
- Aug 6, 202614w ago Insider Cluster Bullish 4/10 Entry $26.20 to $30.52 Now $28.89 +10.27% ▲ +16.49% +18.16% vs SPY
- Aug 5, 202614w ago Insider Buy Bullish 5/10 Entry $26.20 to $30.52 Now $28.89 +10.27% ▲ +16.49% +18.16% vs SPY
- Aug 5, 202614w ago Insider Cluster Neutral 3/10 Entry $26.20 to $30.52 Now $28.89 +10.27% ▲ +16.49% +18.16% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers